Nakamura Takashi, Yamasaki Kazufumi, Morikawa Syunichi, Ohnita Ken, Taura Kouichi, Isomoto Hajime, Mizuta Yohei, Murase Kunihiko, Murata Ikuo, Kohno Shigeru
Nagasaki Municipal Medical Center.
Gan To Kagaku Ryoho. 2002 Jun;29(6):927-32.
TS-1 is a new, oral anticancer agent composed of two modulators, gimeracil (CDHP) and oteracil potassium (Oxo) are mixed with tegafur in a ratio of 1:0.4:1. We report one case of advanced gastric cancer with lung and lymph node metastases that completely responded to TS-1. A 71-year-old woman was admitted to our hospital because of breathlessness. A diagnosis of advanced gastric cancer with extensive lymph node metastases and multiple pulmonary metastases was made. One hundred mg/body/day of TS-1 was orally administrated for 4 weeks. A partial response (PR) was obtained after the first course with regression of multiple pulmonary metastases. After 1 drug-free week, the second course was administered with 120 mg/body/day of TS-1 for 4 weeks. After two courses, the primary tumor was reduced to an ulcer scar with pathological confirmation of a complete disappearance of the cancer tissue. Moreover, computed tomography (CT) showed a complete regression of the extensive lymph node and diffuse lung metastases, for a complete response (CR). The serum level of CEA was reduced from 172.7 ng/ml to 8.1 ng/ml after TS-1 treatment. As for adverse events, only pigmentation of the skin and Grade 2 oral aphta were observed.
替吉奥（TS-1）是一种新型口服抗癌药物，由吉美嘧啶（CDHP）和奥替拉西钾（Oxo）两种调节剂与替加氟按1:0.4:1的比例混合而成。我们报告1例伴有肺和淋巴结转移的晚期胃癌患者对替吉奥完全缓解。一名71岁女性因呼吸困难入院。诊断为伴有广泛淋巴结转移和多发肺转移的晚期胃癌。口服替吉奥100mg/（人·天），持续4周。第一个疗程后获得部分缓解（PR），多发肺转移灶消退。在1周无药期后，进行第二个疗程，口服替吉奥120mg/（人·天），持续4周。两个疗程后，原发肿瘤缩小为溃疡瘢痕，病理证实癌组织完全消失。此外，计算机断层扫描（CT）显示广泛淋巴结和弥漫性肺转移灶完全消退，达到完全缓解（CR）。替吉奥治疗后，癌胚抗原（CEA）血清水平从172.7ng/ml降至8.1ng/ml。至于不良事件，仅观察到皮肤色素沉着和2级口腔炎。
